Please wait

.2
Johnson & Johnson and subsidiaries
Supplementary sales data
(Unaudited; Dollars in Millions)FOURTH QUARTER
Percent Change
Sales to customers by geographic area20252024TotalOperationsCurrency
U.S.$14,195 13,204 7.5 %7.5 — 
Europe5,598 4,921 13.8 5.2 8.6 
Western Hemisphere excluding U.S.1,271 1,135 12.0 11.0 1.0 
Asia-Pacific, Africa3,500 3,260 7.4 7.2 0.2 
International10,369 9,316 11.3 6.6 4.7 
Worldwide$24,564 22,520 9.1 %7.1 2.0 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


























Johnson & Johnson and subsidiaries
Supplementary sales data
(Unaudited; Dollars in Millions)TWELVE MONTHS
Percent Change
Sales to customers by geographic area20252024TotalOperationsCurrency
U.S.$53,752 50,302 6.9 %6.9 — 
Europe21,535 20,212 6.5 2.4 4.1 
Western Hemisphere excluding U.S.4,875 4,714 3.4 8.4 (5.0)
Asia-Pacific, Africa14,031 13,593 3.2 3.1 0.1 
International40,441 38,519 5.0 3.4 1.6 
Worldwide$94,193 88,821 6.0 %5.3 0.7 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.








Johnson & Johnson and subsidiaries
Supplementary sales data
(Unaudited; Dollars in Millions)FOURTH QUARTER
Percent Change
Sales to customers by segment of business20252024TotalOperationsCurrency
Innovative Medicine
U.S.$9,689 8,977 7.9 %7.9 — 
International6,074 5,355 13.4 7.9 5.5 
15,763 14,332 10.0 7.9 2.1 
MedTech
U.S.4,506 4,227 6.6 6.6 — 
International4,295 3,961 8.5 4.9 3.6 
8,801 8,188 7.5 5.8 1.7 
U.S.14,195 13,204 7.5 7.5 — 
International10,369 9,316 11.3 6.6 4.7 
Worldwide$24,564 22,520 9.1 %7.1 2.0 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.























Johnson & Johnson and subsidiaries
Supplementary sales data
(Unaudited; Dollars in Millions)TWELVE MONTHS
Percent Change
Sales to customers by segment of business20252024TotalOperationsCurrency
Innovative Medicine
U.S.$36,344 33,970 7.0 %7.0 — 
International24,057 22,994 4.6 2.9 1.7 
60,401 56,964 6.0 5.3 0.7 
MedTech
U.S.17,408 16,332 6.6 6.6 — 
International16,384 15,525 5.5 4.1 1.4 
33,792 31,857 6.1 5.4 0.7 
U.S.53,752 50,302 6.9 6.9 — 
International40,441 38,519 5.0 3.4 1.6 
Worldwide$94,193 88,821 6.0 %5.3 0.7 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.




Johnson & Johnson and subsidiaries
Condensed consolidated statement of earnings
(Unaudited; in Millions Except Per Share Figures)FOURTH QUARTER
20252024Percent
Increase
(Decrease)
AmountPercent
to Sales		AmountPercent
to Sales
Sales to customers$24,564100.0 $22,520100.0 9.1 
Cost of products sold7,96832.4 7,12831.6 11.8 
Gross Profit16,59667.6 15,39268.4 7.8 
Selling, marketing and administrative expenses6,75327.5 6,45328.6 4.6 
Research and development expense4,25217.3 5,29823.5 (19.7)
In-process research and development impairments810.3 170.1  
Interest (income) expense, net(23)(0.1)(144)(0.6) 
Other (income) expense, net4832.0 (161)(0.7) 
Restructuring840.4 420.2 
Earnings before provision for taxes on income4,96620.2 3,88717.3 27.8 
(Benefit from)/Provision for taxes on income(150)(0.6)4562.1 (132.9)
Net earnings $5,11620.8 $3,43115.2 49.1 
Net earnings per share (Diluted) $2.10$1.4148.9 
Average shares outstanding (Diluted)2,439.02,427.1
Effective tax rate (3.0)%11.7%
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$7,04628.7$5,42124.130.0 
Net earnings$6,00924.5$4,94622.021.5 
Net earnings per share (Diluted)$2.46$2.0420.6 
Effective tax rate 14.7%8.8%
(1) See Reconciliation of Non-GAAP Financial Measures.
(A)    NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.


Johnson & Johnson and subsidiaries
Condensed consolidated statement of earnings
(Unaudited; in Millions Except Per Share Figures)TWELVE MONTHS
20252024Percent
Increase
(Decrease)
AmountPercent
to Sales		AmountPercent
to Sales
Sales to customers$94,193100.0 $88,821100.0 6.0 
Cost of products sold30,25632.1 27,47130.9 10.1 
Gross Profit63,93767.9 61,35069.1 4.2 
Selling, marketing and administrative expenses23,67625.1 22,86925.7 3.5 
Research and development expense14,66515.6 17,23219.4 (14.9)
In-process research and development impairments810.1 2110.2  
Interest (income) expense, net(85)(0.1)(577)(0.6) 
Other (income) expense, net(7,209)(7.6)4,6945.3  
Restructuring2280.2 2340.3  
Earnings before provision for taxes on income32,58134.6 16,68718.8 95.2 
Provision for taxes on income5,7776.1 2,6213.0 120.4 
Net earnings $26,80428.5 $14,06615.8 90.6 
Net earnings per share (Diluted) $11.03$5.7990.5 
Average shares outstanding (Diluted)2,429.42,429.4
Effective tax rate 17.7%15.7%
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$31,68133.6$28,97932.69.3 
Net earnings$26,21527.8$24,24227.38.1 
Net earnings per share (Diluted)$10.79$9.988.1 
Effective tax rate 17.3%16.3%
(1) See Reconciliation of Non-GAAP Financial Measures.
(A)    NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.





Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Fourth Quarter
(Dollars in Millions Except Per Share Data)20252024
Net Earnings, after tax- as reported$5,116 $3,431 
Pre-tax Adjustments
Litigation related854 (16)
Intangible Asset Amortization expense1,186 1,171 
Restructuring related 1
210 62 
Acquisition, integration and divestiture related (190)298 
IPR&D impairments81 17 
(Gains)/losses on securities (100)(68)
Orthopaedics Separation related48 — 
COVID-19 Vaccine related costs — 23 
Medical Device Regulation — 47 
Other(9)— 
Tax Adjustments
Tax impact on special item adjustments 2
(445)(80)
Tax legislation and other tax related(742)61 
Adjusted Net Earnings, after tax$6,009 $4,946 
Average shares outstanding (Diluted)2,439.0 2,427.1 
Adjusted net earnings per share (Diluted)$2.46 $2.04 
Operational adjusted net earnings per share (Diluted)$2.35  
Notes:
1In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $102 million in fiscal 2024 included the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $162 million in the fiscal fourth quarter of 2025 ($307 million Q4 2025 YTD) and $60 million in the fiscal fourth quarter of 2024 ($167 million Q4 2024 YTD) primarily includes costs related to market and product exits. This program was substantially completed in Q4 2025.
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The restructuring expense of $48 million in the fiscal fourth quarter of 2025 ($205 million Q4 2025 YTD) primarily includes costs related to asset impairments and market and product exits. This program is expected to be substantially completed by the end of fiscal year 2026.
2The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.


Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Twelve Months Ended
(Dollars in Millions Except Per Share Data)20252024
Net Earnings, after tax- as reported$26,804 $14,066 
Pre-tax Adjustments
Litigation related(6,040)5,450 
Intangible Asset Amortization expense4,621 4,526 
Restructuring related 1
512 269 
Acquisition, integration and divestiture related 285 1,226 
IPR&D impairments81 211 
(Gains)/losses on securities (427)306 
Orthopaedics Separation related48 — 
COVID-19 Vaccine related costs — 100 
Medical Device Regulation — 204 
Other20 — 
Tax Adjustments
Tax impact on special item adjustments 2
381 (2,135)
Tax legislation and other tax related(70)19 
Adjusted Net Earnings, after tax$26,215 $24,242 
Average shares outstanding (Diluted)2,429.4 2,429.4 
Adjusted net earnings per share (Diluted)$10.79 $9.98 
Operational adjusted net earnings per share (Diluted)$10.58  
Notes:
1In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $102 million in fiscal 2024 included the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $162 million in the fiscal fourth quarter of 2025 ($307 million Q4 2025 YTD) and $60 million in the fiscal fourth quarter of 2024 ($167 million Q4 2024 YTD) primarily includes costs related to market and product exits. This program was substantially completed in Q4 2025.
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The restructuring expense of $48 million in the fiscal fourth quarter of 2025 ($205 million Q4 2025 YTD) primarily includes costs related to asset impairments and market and product exits. This program is expected to be substantially completed by the end of fiscal year 2026.
2The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.






Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Adjusted operational sales growth(A)
Fourth quarter 2025 actual vs. 2024 actual
Segments
 Innovative Medicine MedTech  Total
WW As Reported 10.0%7.5%9.1%
U.S. 7.9%6.6%7.5%
International 13.4%8.5%11.3%
WW Currency 2.11.72.0
U.S. ———
International 5.53.64.7
WW Operational 7.9%5.8%7.1%
U.S. 7.9%6.6%7.5%
International7.9 %4.9%6.6%
Caplyta(1.7)(1.1)
U.S.(2.8)(1.9)
International0.00.0
All Other Acquisitions and Divestitures (A&D)0.00.10.1
U.S. 0.00.10.1
International 0.10.20.2
WW Adjusted Operational Ex A&D6.2%5.9%6.1%
U.S.5.1%6.7%5.7%
International8.0%5.1%6.8%
Note: Percentages are based on actual, non-rounded figures and may not sum
(A)    NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.


Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Adjusted operational sales growth(A)
Twelve months 2025 actual vs. 2024 actual
Segments
 Innovative Medicine MedTech  Total
WW As Reported 6.0%6.1%6.0%
U.S. 7.0%6.6%6.9%
International 4.6%5.5%5.0%
WW Currency 0.70.70.7
U.S. ———
International 1.71.41.6
WW Operational 5.3%5.4%5.3%
U.S. 7.0%6.6%6.9%
International2.9%4.1%3.4%
Shockwave(1.4)(0.5)
U.S.(2.1)(0.7)
International(0.5)(0.2)
Caplyta(1.2)(0.7)
U.S.(2.1)(1.4)
International0.00.0
All Other Acquisitions and Divestitures (A&D)0.00.30.1
U.S. 0.00.30.1
International 0.10.20.1
WW Adjusted Operational Ex A&D4.1%4.3%4.2%
U.S.4.9%4.8%4.9%
International3.0%3.8%3.3%
Note: Percentages are based on actual, non-rounded figures and may not sum
(A)    NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.






Johnson & Johnson
Segment sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)
ONCOLOGY
US$3,793 3,019 25.6 %25.6 %—%
Intl3,069 2,476 23.9 17.3 6.6 
WW6,861 5,497 24.8 21.9 2.9 
CARVYKTI
US420 304 38.238.2— 
Intl135 31 ***
WW555 334 65.863.22.6
DARZALEX
US2,332 1,799 29.6 29.6 — 
Intl1,571 1,285 22.3 16.2 6.1 
WW3,903 3,084 26.6 24.1 2.5 
ERLEADA
US405 342 18.6 18.6 — 
Intl554 442 25.3 17.5 7.8 
WW959 784 22.4 18.0 4.4 
IMBRUVICA
US207 250 (17.4)(17.4)— 
Intl478 481 (0.8)(7.5)6.7 
WW684 731 (6.5)(10.9)4.4 
RYBREVANT / LAZCLUZE(3)
US146 101 45.645.6— 
Intl70 21 ***
WW216 122 78.076.51.5
TALVEY
US105 68 53.8 53.8 — 
Intl44 17 ***
WW149 85 75.8 73.1 2.7 
TECVAYLI
US110 108 2.7 2.7 — 
Intl66 38 72.265.17.1
WW176 146 20.8 18.9 1.9 
ZYTIGA / abiraterone acetate
US5 9 (41.4)(41.4)— 
Intl115 127 (9.9)(11.1)1.2 
WW119 135 (11.9)(13.0)1.1 
OTHER ONCOLOGY
US61 39 54.8 54.8 — 
Intl39 36 8.4 3.0 5.4 
WW100 75 32.9 30.3 2.6 
See footnotes at end of schedule



Johnson & Johnson
Segment sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
IMMUNOLOGY
US$2,495 2,856 (12.6)%(12.6)%—%
Intl1,364 1,383 (1.4)(5.5)4.1 
WW3,860 4,238 (8.9)(10.3)1.4 
REMICADE
US248 231 7.1 7.1 — 
US Exports(4)
11 9 17.1 17.1 — 
Intl110 117 (5.6)(7.3)1.7 
WW370 359 3.2 2.6 0.6 
SIMPONI / SIMPONI ARIA
US287 262 9.6 9.6 — 
Intl345 321 7.4 3.7 3.7 
WW632 583 8.4 6.4 2.0 
STELARA
US766 1,699 (54.9)(54.9)— 
Intl462 650 (28.8)(32.3)3.5 
WW1,230 2,349 (47.7)(48.6)0.9 
TREMFYA
US1,145 654 75.1 75.1 — 
Intl445 295 50.9 44.0 6.9 
WW1,589 949 67.6 65.4 2.2 
OTHER IMMUNOLOGY
US39 0 **— 
Intl2 0 ***
WW40 0 ***
NEUROSCIENCE
US1,439 1,148 25.4 25.4 — 
Intl675 628 7.6 4.3 3.3 
WW2,115 1,775 19.1 17.9 1.2 
CAPLYTA(5)
US249 — **— 
Intl— — — — — 
WW249 — **— 
CONCERTA / methylphenidate
US6 33 (79.6)(79.6)— 
Intl126 125 (0.3)(1.4)1.1 
WW132 159 (17.1)(17.8)0.7 
INVEGA SUSTENNA / XEPLION / INVEGA
TRINZA / TREVICTA
US704 796 (11.5)(11.5)— 
Intl281 267 5.2 1.9 3.3 
WW986 1,063 (7.3)(8.2)0.9 
SPRAVATO
US438 269 63.0 63.0 — 
Intl64 28 ***
WW503 297 69.0 67.8 1.2 
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
OTHER NEUROSCIENCE
US$40 49 (18.3)%(18.3)%—%
Intl205 206 (0.7)(4.3)3.6 
WW245 255 (4.1)(6.9)2.8 
PULMONARY HYPERTENSION
US865 819 5.7 5.7 — 
Intl319 274 16.4 12.2 4.2 
WW1,184 1,092 8.4 7.4 1.0 
OPSUMIT / OPSYNVI
US458 408 11.9 11.9 — 
Intl185 162 14.8 10.9 3.9 
WW643 570 12.7 11.6 1.1 
UPTRAVI
US397 391 1.6 1.6 — 
Intl94 75 26.9 20.8 6.1 
WW491 465 5.7 4.7 1.0 
OTHER PULMONARY HYPERTENSION
US10 19 (43.7)(43.7)— 
Intl39 38 2.6 1.2 1.4 
WW49 57 (12.5)(13.5)1.0 
INFECTIOUS DISEASES
US303 331 (8.5)(8.5)— 
Intl505 443 13.9 5.6 8.3 
WW807 774 4.3 (0.4)4.7 
EDURANT / rilpivirine
US5 7 (39.1)(39.1)— 
Intl379 315 20.6 11.1 9.5 
WW383 322 19.2 9.9 9.3 
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US294 321 (8.4)(8.4)— 
Intl89 86 3.6 (2.9)6.5 
WW383 407 (5.8)(7.2)1.4 
OTHER INFECTIOUS DISEASES
US4 1 92.9 92.9 — 
Intl37 43 (14.5)(18.0)3.5 
WW40 45 (9.9)(13.2)3.3 
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
CARDIOVASCULAR / METABOLISM / OTHER
US$794 805 (1.4)%(1.4)%—%
Intl142 153 (6.3)(10.7)4.4 
WW936 957 (2.2)(2.9)0.7 
XARELTO
US687 676 1.7 1.7 — 
Intl— — — — — 
WW687 676 1.7 1.7 — 
OTHER
US107 130 (17.4)(17.4)— 
Intl142 153 (6.3)(10.7)4.4 
WW249 281 (11.4)(13.8)2.4 
TOTAL INNOVATIVE MEDICINE
US9,6898,9777.9 7.9 — 
Intl6,0745,35513.4 7.9 5.5 
WW$15,763 14,33210.0%7.9%2.1 %
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20252024Reported
Operational(1)
Currency
MEDTECH SEGMENT(2)
CARDIOVASCULAR
US$1,374 1,221 12.5%12.5%—%
Intl925 841 10.1 6.8 3.3 
WW2,299 2,062 11.5 10.1 1.4 
ELECTROPHYSIOLOGY
US746 681 9.5 9.5 — 
Intl679 640 6.2 3.2 3.0 
WW1,425 1,321 7.9 6.5 1.4 
ABIOMED
US358 308 16.5 16.5 — 
Intl102 77 33.1 25.4 7.7 
WW460 384 19.8 18.3 1.5 
SHOCKWAVE
US238 202 18.018.0— 
Intl80 56 42.340.71.6 
WW318 258 23.322.90.4 
OTHER CARDIOVASCULAR
US31 31 (0.1)(0.1)— 
Intl64 68 (6.7)(8.8)2.1 
WW95 99 (4.6)(6.1)1.5 
ORTHOPAEDICS
US1,520 1,460 4.2 4.2 — 
Intl918 856 7.3 2.3 5.0 
WW2,438 2,315 5.3 3.5 1.8 
HIPS
US284 272 4.3 4.3 — 
Intl154 146 5.5 0.4 5.1 
WW439 418 4.7 2.9 1.8 
KNEES
US251 238 5.1 5.1 — 
Intl181 160 13.7 9.2 4.5 
WW432 398 8.6 6.8 1.8 
TRAUMA
US543 514 5.6 5.6 — 
Intl270 250 7.9 2.7 5.2 
WW813 764 6.4 4.7 1.7 
SPINE, SPORTS & OTHER
US442 434 1.9 1.9 — 
Intl312 300 4.2 (0.7)4.9 
WW756 735 2.8 0.8 2.0 
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20252024Reported
Operational(1)
Currency
MEDTECH SEGMENT(2)(Continued)
SURGERY
US$1,081 1,038 4.2 %4.2 %— %
Intl1,563 1,469 6.4 3.4 3.0 
WW2,644 2,507 5.5 3.7 1.8 
ADVANCED
US489 478 2.5 2.5 — 
Intl687 673 1.9 (0.8)2.7 
WW1,175 1,151 2.2 0.6 1.6 
GENERAL
US592 560 5.6 5.6 — 
Intl876 795 10.2 6.9 3.3 
WW1,468 1,357 8.3 6.3 2.0 
VISION
US531 509 4.3 4.3 — 
Intl889 794 11.9 8.5 3.4 
WW1,420 1,303 8.9 6.8 2.1 
CONTACT LENSES / OTHER
US417 396 5.3 5.3 — 
Intl592 541 9.3 5.3 4.0 
WW1,008 937 7.6 5.3 2.3 
SURGICAL
US113 113 0.6 0.6 — 
Intl297 252 17.7 15.3 2.4 
WW411 365 12.4 10.8 1.6 
TOTAL MEDTECH
US4,506 4,227 6.6 6.6 — 
Intl4,295 3,961 8.5 4.9 3.6 
WW$8,801 8,188 7.5%5.8%1.7%
See footnotes at end of schedule







Johnson & Johnson
Segment sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)
ONCOLOGY
US$13,659 10,854 25.8 %25.8 %—%
Intl11,721 9,926 18.1 15.6 2.5 
WW25,380 20,781 22.1 20.9 1.2 
CARVYKTI
US1,492 869 71.671.6— 
Intl395 94 ***
WW1,887 963 95.994.31.6
DARZALEX
US8,266 6,588 25.5 25.5 — 
Intl6,085 5,082 19.7 17.5 2.2 
WW14,351 11,670 23.0 22.0 1.0 
ERLEADA
US1,453 1,282 13.4 13.4 — 
Intl2,121 1,717 23.5 20.1 3.4 
WW3,574 2,999 19.2 17.2 2.0 
IMBRUVICA
US892 1,020 (12.5)(12.5)— 
Intl1,931 2,018 (4.3)(6.7)2.4 
WW2,823 3,038 (7.1)(8.6)1.5 
RYBREVANT / LAZCLUZE(3)
US534 257 **— 
Intl200 70 ***
WW734 327 ***
TALVEY
US340 241 40.9 40.9 — 
Intl123 46 ***
WW463 287 61.3 60.3 1.0 
TECVAYLI
US444 418 6.3 6.3 — 
Intl226 131 72.8 70.4 2.4 
WW670 549 22.1 21.5 0.6 
ZYTIGA / abiraterone acetate
US23 34 (33.2)(33.2)— 
Intl480 597 (19.7)(20.5)0.8 
WW502 631 (20.4)(21.2)0.8 
OTHER ONCOLOGY
US214 145 47.5 47.5 — 
Intl162 172 (6.0)(7.8)1.8 
WW376 317 18.5 17.5 1.0 
See footnotes at end of schedule



Johnson & Johnson
Segment sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
IMMUNOLOGY
US$9,872 11,355 (13.1)%(13.1)%—%
Intl5,856 6,473 (9.5)(10.2)0.7 
WW15,728 17,828 (11.8)(12.0)0.2 
REMICADE
US1,171 1,009 16.0 16.0 — 
US Exports(4)
74 98 (24.8)(24.8)— 
Intl523 497 5.3 6.2 (0.9)
WW1,768 1,605 10.2 10.5 (0.3)
SIMPONI / SIMPONI ARIA
US1,193 1,082 10.3 10.3 — 
Intl1,475 1,108 33.1 32.8 0.3 
WW2,668 2,190 21.8 21.7 0.1 
STELARA
US3,847 6,720 (42.7)(42.7)— 
Intl2,230 3,641 (38.7)(39.3)0.6 
WW6,078 10,361 (41.3)(41.5)0.2 
TREMFYA
US3,529 2,443 44.5 44.5 — 
Intl1,626 1,227 32.5 30.4 2.1 
WW5,155 3,670 40.5 39.8 0.7 
OTHER IMMUNOLOGY
US59 3 **— 
Intl2 0 ***
WW61 3 ***
NEUROSCIENCE
US5,151 4,398 17.1 17.1 — 
Intl2,686 2,718 (1.2)(1.8)0.6 
WW7,837 7,115 10.1 9.9 0.2 
CAPLYTA(5)
US700 — **— 
Intl— — — — — 
WW700 — **— 
CONCERTA / methylphenidate
US82 134 (38.6)(38.6)— 
Intl502 507 (1.2)(0.7)(0.5)
WW584 641 (9.0)(8.6)(0.4)
INVEGA SUSTENNA / XEPLION / INVEGA
TRINZA / TREVICTA
US2,725 3,125 (12.8)(12.8)— 
Intl1,085 1,097 (1.1)(1.8)0.7 
WW3,810 4,222 (9.8)(9.9)0.1 
SPRAVATO
US1,485 929 59.9 59.9 — 
Intl210 148 41.9 39.1 2.8 
WW1,696 1,077 57.4 57.0 0.4 
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
OTHER NEUROSCIENCE
US$159 210 (24.5)%(24.5)%—%
Intl889 965 (7.9)(8.7)0.8 
WW1,048 1,175 (10.9)(11.5)0.6 
PULMONARY HYPERTENSION
US3,223 3,143 2.6 2.6 — 
Intl1,214 1,140 6.5 4.9 1.6 
WW4,437 4,282 3.6 3.2 0.4 
OPSUMIT / OPSYNVI
US1,633 1,557 4.8 4.8 — 
Intl692 668 3.7 2.1 1.6 
WW2,325 2,225 4.5 4.0 0.5 
UPTRAVI
US1,536 1,511 1.7 1.7 — 
Intl366 307 19.4 17.4 2.0 
WW1,902 1,817 4.7 4.3 0.4 
OTHER PULMONARY HYPERTENSION
US54 75 (27.0)(27.0)— 
Intl155 165 (6.2)(6.8)0.6 
WW209 240 (12.7)(13.0)0.3 
INFECTIOUS DISEASES
US1,264 1,354 (6.6)(6.6)— 
Intl1,977 2,042 (3.2)(6.5)3.3 
WW3,241 3,396 (4.6)(6.5)1.9 
EDURANT / rilpivirine
US26 31 (18.4)(18.4)— 
Intl1,461 1,241 17.7 13.0 4.7 
WW1,486 1,272 16.9 12.2 4.7 
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US1,226 1,311 (6.5)(6.5)— 
Intl353 401 (11.9)(13.7)1.8 
WW1,579 1,712 (7.7)(8.1)0.4 
OTHER INFECTIOUS DISEASES
US12 11 6.6 6.6 — 
Intl163 401 (59.3)(59.5)0.2 
WW175 412 (57.5)(57.7)0.2 
See footnotes at end of schedule
                


Johnson & Johnson
Segment sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20252024Reported
Operational(1)
Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
CARDIOVASCULAR / METABOLISM / OTHER
US$3,175 2,866 10.8%10.8%—%
Intl603696(13.3)(13.8)0.5 
WW3,7783,5626.1 6.0 0.1 
XARELTO
US2,633 2,373 11.0 11.0 — 
Intl— — — — — 
WW2,633 2,373 11.0 11.0 — 
OTHER
US542 494 9.8 9.8 — 
Intl603 696 (13.3)(13.8)0.5 
WW1,145 1,189 (3.7)(4.0)0.3 
TOTAL INNOVATIVE MEDICINE
US36,34433,9707.0 7.0 — 
Intl24,05722,9944.6 2.9 1.7 
WW$60,401 56,9646.0%5.3%0.7%
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20252024Reported
Operational(1)
Currency
MEDTECH SEGMENT(2)
CARDIOVASCULAR
US$5,305 4,513 17.5%17.5%—%
Intl3,623 3,194 13.4 11.9 1.5 
WW8,928 7,707 15.8 15.2 0.6 
ELECTROPHYSIOLOGY
US2,891 2,738 5.6 5.6 — 
Intl2,743 2,529 8.5 7.3 1.2 
WW5,634 5,267 7.0 6.4 0.6 
ABIOMED
US1,393 1,213 14.9 14.9 — 
Intl358 284 26.4 22.0 4.4 
WW1,751 1,496 17.1 16.2 0.9 
SHOCKWAVE
US897 442 **— 
Intl249 122 ***
WW1,146 564 ***
OTHER CARDIOVASCULAR
US124 120 3.1 3.1 — 
Intl273 260 4.9 4.1 0.8 
WW397 380 4.3 3.8 0.5 
ORTHOPAEDICS
US5,720 5,689 0.5 0.5 — 
Intl3,538 3,470 2.0 (0.2)2.2 
WW9,258 9,158 1.1 0.3 0.8 
HIPS
US1,080 1,057 2.1 2.1 — 
Intl594 581 2.2 0.1 2.1 
WW1,674 1,638 2.1 1.4 0.7 
KNEES
US924 922 0.2 0.2 — 
Intl663 623 6.5 4.6 1.9 
WW1,587 1,545 2.7 2.0 0.7 
TRAUMA
US2,058 2,013 2.2 2.2 — 
Intl1,088 1,036 5.0 2.7 2.3 
WW3,146 3,049 3.2 2.4 0.8 
SPINE, SPORTS & OTHER
US1,658 1,696 (2.2)(2.2)— 
Intl1,193 1,230 (3.0)(5.3)2.3 
WW2,852 2,926 (2.5)(3.5)1.0 
See footnotes at end of schedule


Johnson & Johnson
Segment sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20252024Reported
Operational(1)
Currency
MEDTECH SEGMENT(2)(Continued)
SURGERY
US$4,157 4,003 3.9 %3.9 %— %
Intl5,980 5,842 2.4 1.5 0.9 
WW10,137 9,845 3.0 2.5 0.5 
ADVANCED
US1,900 1,838 3.4 3.4 — 
Intl2,678 2,650 1.0 0.1 0.9 
WW4,577 4,488 2.0 1.5 0.5 
GENERAL
US2,258 2,165 4.3 4.3 — 
Intl3,302 3,192 3.4 2.7 0.7 
WW5,560 5,358 3.8 3.3 0.5 
VISION
US2,225 2,128 4.6 4.6 — 
Intl3,243 3,018 7.4 5.9 1.5 
WW5,468 5,146 6.3 5.3 1.0 
CONTACT LENSES / OTHER
US1,754 1,684 4.1 4.1 — 
Intl2,157 2,049 5.3 3.2 2.1 
WW3,910 3,733 4.8 3.6 1.2 
SURGICAL
US471 444 6.1 6.1 — 
Intl1,086 969 12.1 11.6 0.5 
WW1,558 1,413 10.2 9.9 0.3 
TOTAL MEDTECH
US17,408 16,332 6.6 6.6 — 
Intl16,384 15,525 5.5 4.1 1.4 
WW$33,792 31,857 6.1%5.4%0.7 %
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
*    Percentage greater than 100% or not meaningful
(1)Operational growth excludes the effect of translational currency
(2)Unaudited
(3)Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE
(4)Reported as U.S. sales
(5)Acquired with Intra-Cellular Therapies on April 2, 2025